Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer.
Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer.
复制标题
非小细胞肺癌患者致癌状态与静脉血栓栓塞风险之间的关联
DOI：
10.1186/s12931-018-0791-2
复制
发表时间：
2018-05-09
影响因子：
5.8
通讯作者：
Zhang Y
中科院分区：
文献类型：
--
作者：
Dou F;Li H;Zhu M;Liang L;Zhang Y;Yi J;Zhang Y
临床前数据表明，癌基因（EGFR和KRAS）事件调节肿瘤促凝血活性。然而，很少有研究前瞻性地研究EGFR或KRAS突变的存在与非小细胞肺癌（NSCLC）患者发生静脉血栓栓塞（VTE）之间的临床相关性。共纳入了605例新诊断的中国NSCLC患者，并随访了最长4.5年。EGFR和KRAS突变在入选时通过扩增难治性突变系统聚合酶链反应方法确定。主要结局为客观证实的VTE。在605例患者中，40.3%（244例）的患者存在EGFR突变，10.2%（62例）的患者存在KRAS突变。在包括年龄、性别、肿瘤组织学、肿瘤分期、体能状态、EGFR和KRAS状态的多变量分析中，EGFR野生型（亚分布风险比1.81，95%置信区间1.07-3.07）与VTE风险增加相关。在竞争风险分析中，1年后发生VTE的概率在有EGFR突变的患者中为8.3%，在无EGFR突变的患者中为13.2%; 2年后，相应的风险为9.7%和15.5%（灰色检验P = 0.047）。EGFR突变与中国NSCLC患者的VTE风险呈负相关。
Preclinical data suggest that oncogene (EGFR and KRAS) events regulate tumor procoagulant activity. However, few studies have prospectively investigated the clinical relevance between the presence of EGFR or KRAS mutations and occurrence of venous thromboembolism(VTE) in patients with non-small cell lung cancer (NSCLC). A total of 605 Chinese patients with newly diagnosed NSCLC were included and were followed for a maximum period of 4.5 years. EGFR and KRAS mutations were determined by amplification refractory mutation system polymerase chain reaction method at inclusion. The main outcome was objectively confirmed VTE. Of the 605 patients, 40.3% (244) had EGFR mutations and 10.2% (62) of patients had KRAS mutations. In multivariable analysis including age, sex, tumor histology, tumor stage, performance status, EGFR and KRAS status, EGFR wild-type (sub-distribution hazard ratio 1.81, 95% confidence interval 1.07–3.07) were associated with the increased risk of VTE. In competing risk analysis, the probability of developing VTE was 8.3% in those with and 13.2% in those without EGFR mutations after 1 year; after 2 years, the corresponding risks were 9.7 and 15.5% (Gray test P = 0.047). EGFR mutations have a negative association with the risk of VTE in Chinese patients with NSCLC.
登录
查看更多内容
影响因子：
6.2
作者：
Steuer, Conor E.;Behera, Madhusmita;Berry, Lynne;Kim, Sungjin;Rossi, Michael;Sica, Gabriel;Owonikoko, Taofeek K.;Johnson, Bruce E.;Kris, Mark G.;Bunn, Paul A.;Khuri, Fadlo R.;Garon, Edward B.;Ramalingam, Suresh S.
通讯作者：
Ramalingam, Suresh S.
影响因子：
9.3
作者：
Regina, Sandra;Valentin, Jean-Baptiste;Gruel, Yves
通讯作者：
Gruel, Yves
影响因子：
6.7
作者：
Lee, Yun-Gyoo;Kim, Inho;Heo, Dae Seog
通讯作者：
Heo, Dae Seog
微粒作为癌症血液凝结的生物标志物。
DOI：
10.4137/bic.s30347
发表时间：
2015
期刊：
Biomarkers in cancer
影响因子：
--
作者：
Nomura S;Niki M;Nisizawa T;Tamaki T;Shimizu M
通讯作者：
Shimizu M
亚洲晚期非小细胞腺癌组织学肺癌患者 EGFR 突变的前瞻性分子流行病学研究 (PIONEER)。
DOI：
10.1097/jto.0000000000000033
发表时间：
2014-02
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Shi Y;Au JS;Thongprasert S;Srinivasan S;Tsai CM;Khoa MT;Heeroma K;Itoh Y;Cornelio G;Yang PC
通讯作者：
Yang PC